Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR-T Cells Patents – Business Wire (press release)
|
Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR–T Cells Patents
Business Wire (press release) Celyad (Paris:CYAD) (Brussels:CYAD), a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad's US patents for the production of allogeneic CAR–T cells. This license … |
